Altimmune (LTS:0A4C) Total Stockholders Equity : $123.51 Mil (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Altimmune Total Stockholders Equity?

Altimmune's Total Stockholders Equity for the quarter that ended in Dec. 2024 was $123.51 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Altimmune's Book Value per Share for the quarter that ended in Dec. 2024 was $1.71. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Altimmune's Debt-to-Equity for the quarter that ended in Dec. 2024 was 0.01.

Altimmune Total Stockholders Equity Historical Data

The historical data trend for Altimmune's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Altimmune Total Stockholders Equity Chart

Altimmune Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Stockholders Equity

Get a 7-Day Free Trial

225.88

199.14

185.29

194.10

123.51

Altimmune Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Stockholders Equity	Get a 7-Day Free Trial															194.10	172.94	152.53	133.38	123.51

Altimmune (LTS:0A4C) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Altimmune's Book Value per Share for the quarter that ended in Dec. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(123.508	-	0)	/	72.353
	=	1.71

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Altimmune's Debt-to-Equity for the quarter that ended in Dec. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.279	+	1.402)	/	123.508
	=	0.01

Altimmune Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Altimmune's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Altimmune Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Altimmune Inc (LTS:0A4C) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

ALT:USA 3G0:Germany 3G0:Germany

Address

910 Clopper Road, Suite 201S, Gaithersburg, MD, USA, 20878

Website

https://www.altimmune.com

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Altimmune Headlines

No Headlines